ArticleDiabetes, obesity & metabolism2026
Association Between SGLT2 Inhibitors and DPP-4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case-Based Analyses.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsThe Korean national health insurance claims database was utilised to investigate the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase-4 inhibitors (DPP-4i) and the risk of acute pancreatitis (AP). MATERIALS AND
methodsPatients with type 2 diabetes mellitus prescribed DPP-4i or SGLT2i at least once between January, 2018 and December, 2020 were included. AP was defined by ICD-10 code K85.x in either the principal or first additional diagnosis during hospital admission. Prescription status of the anti-diabetic medications was compared between the hazard period (30 days before AP) and the preceding control periods of the same length with 120 days of washout periods, using conditional logistic regression adjusted for other anti-diabetic and AP-related medications. To account for increasing exposure trends, the case-case-time-control design was applied to minimise bias. A nested case-control study was conducted to ensure the robustness of the controls defined within the current type 2 diabetes mellitus cohort.
resultsA total of 7219 AP cases were included. In the case-case-time-control analysis, the risk between the AP and SGLT2i (adjusted odds ratio, 95% confidence interval 0.84, 0.52-1.35) and DPP-4i (aOR 0.93, 95% CI 0.75-1.15) was negligible. The nested case-control study further supported these findings, as the use of SGLT2i (aOR 1.05, 95% CI 0.91-1.21) or DPP-4i (aOR 1.01, 95% CI 0.94-1.09) within a 30-day time window was not associated with the risk of AP.
conclusionsNeither SGLT2i nor DPP-4i is associated with an increased risk of AP in patients with type 2 diabetes mellitus after accounting for prescription trends.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.